 |
Iroko Pharmaceuticals, LLC
Navy Yard Corporate Center
One Crescent Drive
Suite 400
Philadelphia, PA 19112
p 267.546.3003
f 267.546.3004
Contact Us
|
|
iCeutica Completes GMP Scale-Up for its Nano-Sized Products
PHILADELPHIA, PA, June 19, 2008 — iCeutica, Inc. announces that the first GMP clinical supplies have been manufactured for its partner, Iroko
Pharmaceuticals, utilizing iCeutica’s proprietary nano-sizing technology. The completion of the manufacturing campaign represents an important technical
and commercial validation of the iCeutica platform.
“We are very pleased to achieve this significant milestone for iCeutica. Our nano-sizing technology has progressed from pilot plant scale to commercial
operation inside a GMP facility and is producing the consistent, quality products that we projected,” said iCeutica President and CEO, Matt Callahan.
Iroko and iCeutica are collaborating on the application of iCeutica’s nano-sizing platform to reformulate certain proprietary Iroko products. Iroko is
guiding the progression of these reformulated products through the regulatory process, clinical trials and ultimate commercial launch.
“The products Iroko is developing with iCeutica will have significant and relevant benefits for patients, with enhanced onset of action, reduction in
food-fast effects and potentially reduced side effects,” said Iroko President and CEO, John Vavricka.
“iCeutica’s nano-sizing platform is broadly applicable to a wide range of poorly soluble drug compounds and provides a novel and exciting approach to
formulation development and drug product manufacturing. We look forward to working with our partners and on our internal pipeline in maximizing the potential
of this important new technology,” said Mr. Callahan.
About iCeutica: iCeutica commercializes products developed utilizing its proprietary nano-sizing platform. The technology is an enabling
reformulation platform, which provides simple and scalable processes to reformulate development stage and marketed products with solubility, delivery or
bioavailability challenges.
About Iroko Pharmaceuticals LLC: Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops
and maximizes the potential of currently marketed pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and
marketing efforts and product life cycle management activities including development of relevant formulations to improve patient treatment.
|
|
ALL PRESS RELEASES
New Data Shows Anticlotting Medicine, Tirofiban, Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, After
Elective Coronary Angioplasty
09/02/2008
New Data Shows Acute Heart Attack Patients Given High-Dose Bolus (HDB) Tirofiban In-Ambulance, with Standard of Care,
Significantly Improves Clinical Outcomes
08/31/2008
iCeutica Completes GMP Scale-Up for its Nano-Sized Products
06/19/2008
Tirofiban Significantly Reduced Residual ST-Segment Deviation After Primary PCI in Patients with ST-Elevation Myocardial Infarction in Ongoing
Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 Trial
04/01/2008
High-Dose Tirofiban was as Effective as Abciximab in Reducing ST-Segment Elevation in STEMI Patients in the Multicentre
Evaluation of Single High-Dose Bolus Tirofiban versus Abciximab with Sirolimus Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study
03/30/2008
Chief Medical Officer Announces Intention to Retire
03/10/2008
Iroko Pharmaceuticals Acquires Rights to Cardiovascular Product from Merck & Co., Inc.
01/30/2008
Iroko Pharmaceuticals Acquires Canadian Rights to Lilly Anti-Infective Product
10/10/2007
Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
06/29/2007
Iroko Pharmaceuticals Appoints Susan F. Langer M.D. as Chief Medical Officer and Vice President of Research & Development
06/07/2007
Iroko Pharmaceuticals Appoints John Vavricka as President and Chief Executive Officer
04/18/2007
Iroko Pharmaceuticals Acquires Rights to Two Pharmaceutical Products from Merck & Company, Inc.
03/26/2007
|
